Tidal Investments LLC Cuts Position in DexCom, Inc. (NASDAQ:DXCM)

Tidal Investments LLC lessened its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 24.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,812 shares of the medical device company's stock after selling 8,930 shares during the quarter. Tidal Investments LLC's holdings in DexCom were worth $2,163,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Forvis Mazars Wealth Advisors LLC increased its holdings in DexCom by 0.7% in the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock worth $1,359,000 after acquiring an additional 118 shares in the last quarter. Principal Securities Inc. increased its holdings in DexCom by 3.4% in the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock worth $316,000 after acquiring an additional 135 shares in the last quarter. Larson Financial Group LLC increased its holdings in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after acquiring an additional 137 shares in the last quarter. Nia Impact Advisors LLC increased its holdings in DexCom by 1.4% in the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after acquiring an additional 140 shares in the last quarter. Finally, Level Four Advisory Services LLC increased its holdings in DexCom by 1.1% in the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock worth $1,026,000 after acquiring an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on DXCM. Cfra Research raised shares of DexCom to a "hold" rating in a report on Friday, March 21st. Citigroup reaffirmed a "buy" rating and set a $102.00 target price (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Barclays upped their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Finally, Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.00.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares of the company's stock, valued at approximately $7,432,268.76. This represents a 10.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the sale, the executive vice president now directly owns 135,482 shares in the company, valued at $10,002,636.06. This represents a 4.91% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,926 shares of company stock valued at $4,734,384 over the last 90 days. 0.32% of the stock is owned by insiders.

DexCom Trading Up 1.7%

NASDAQ DXCM traded up $1.44 during trading hours on Wednesday, reaching $86.77. The company had a trading volume of 705,610 shares, compared to its average volume of 4,348,397. The stock has a 50-day moving average of $73.97 and a 200 day moving average of $78.41. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $128.63. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $34.02 billion, a P/E ratio of 60.67, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the previous year, the company earned $0.32 EPS. The company's quarterly revenue was up 12.5% compared to the same quarter last year. As a group, research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.